11C-YJH08 PET Imaging for the Detection of Glucocorticoid Receptor Expression in Patients With Metastatic Prostate Cancer
Status:
Recruiting
Trial end date:
2022-10-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can
be useful for detecting certain cell receptor expression in tumor cells in patients with
prostate cancer that has spread to other parts of the body (metastatic). 11C-YJH08 is a
small-molecule radiotracer that binds to receptors on cells (glucocorticoid receptor) so that
they show up better on the PET scan. Anti-hormone therapy (including enzalutamide) can cause
more glucocorticoid receptors to be produced in tumor cells, which can make the tumor cells
resist hormone therapies. If researchers can find a better way to detect whether
glucocorticoid receptors are increasing during therapy, it may lead to more successful
therapies using glucocorticoid receptor antagonists.
Phase:
Phase 1
Details
Lead Sponsor:
Michael Evans
Collaborators:
National Institute of Mental Health (NIMH) U.S. Army Medical Research Acquisition Activity